My DC Visit Resulted in More Clarity Than Questions: Four Takeaways

Posted by Pratap Khedkar on Fri, Feb 10, 2017

Like so many millions of people—or so few, depending on whom you ask—I spent a couple of days in our nation’s capital during the Trump administration’s first week, but I wasn’t out on the National Mall with a cleverly worded sign. I was there to join other healthcare industry leaders, thought leaders and pundits as they discussed the evolving healthcare environment. I wanted to get a sense for what may be coming down the pike, and based on what I heard, it seems that the only constant is change—and pharmaceutical leaders better get ready to help shape this change. Here are four of my takeaways:


>
Read More

Will an Unlikely Dynamic Duo Take On Hepatitis C?

Posted by Paul Darling on Tue, Nov 17, 2015

As a number of healthcare partnerships, mostly in the form of accountable care organizations (ACOs), have recently formed, agreements between stakeholders outside of these ACOs are less common as many companies see the healthcare market as a zero-sum game. Contract negotiations between payers and providers over reimbursement levels or the exclusion of Gilead’s hepatitis C drugs by Express Scripts are more representative of the conflicts between stakeholders in the healthcare ecosystem.


>
Read More